Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
165 hedge funds and large institutions have $824M invested in Aimmune Therapeutics in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 72 increasing their positions, 37 reducing their positions, and 22 closing their positions.
95% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 37
69% more call options, than puts
Call options by funds: $8.66M | Put options by funds: $5.11M
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
16% more capital invested
Capital invested by funds: $712M → $824M (+$113M)
2% more funds holding
Funds holding: 161 → 165 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25.9M |
| 2 |
First Manhattan
New York
|
+$17.4M |
| 3 |
AC
Armistice Capital
New York
|
+$5.5M |
| 4 |
SCA
Southpoint Capital Advisors
New York
|
+$5.09M |
| 5 |
BlackRock
New York
|
+$5.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$28.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.1M |
| 3 |
Morgan Stanley
New York
|
-$11.3M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$11.2M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.01M |
AIMT Hedge Fund Activity: Q2 2020 in Review
165 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2020, worth a combined $824M — up 16% from $712M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AIMT positions and 22 closed out — a net gain of 4 holders — while 72 added to existing stakes and 37 trimmed.
The largest buyer was State Street, adding an estimated $25.9M. The largest seller was Victory Capital Management, cutting an estimated $28.9M.
- 165 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2020, up from 161 in Q1 2020.
- Funds reported $824M of Aimmune Therapeutics stock for Q2 2020, up 16% quarter-over-quarter.
- 26 funds opened new Aimmune Therapeutics positions in Q2 2020 and 22 closed out, a net change of +4 holders.
- The largest Aimmune Therapeutics buyer in Q2 2020 was State Street, an estimated $25.9M added.
- The largest Aimmune Therapeutics seller in Q2 2020 was Victory Capital Management, an estimated $28.9M sold.
Based on aggregated 13F filings for Q2 2020.